The Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership (the "Partnership") respects the interest that visitors to our Web sites have in understanding what information is collected electronically, how it is collected, how it is used and to whom it is or may be disclosed. The Partnership has developed this online privacy policy to address those questions.
You should be aware that the Partnership is not a health-care provider (e.g. doctor, hospital, pharmacist, etc.) and is generally not subject to the Privacy Rule under the Health Insurance Portability and Accountability Act (HIPAA), which imposes strict requirements on health-care providers relating to individually identifiable health-care information.
This policy applies only to information collected on Web sites that are directly linked to this policy, and does not apply to information collected in other areas, whether online or offline. This policy does not apply to third-party Web sites that may be accessed through a link from a site covered by this policy. You should review the privacy policies of any third-party Web sites to understand how that site collects, uses and discloses any Personal Information (as defined below).
This policy addresses only information which is or may be collected on our U.S. Web sites—which are NOT intended to be used by non-US residents.
Our U.S. Web sites are not intended for, or designed to attract, individuals under the age of 13, or to collect Personal Information (as defined below) from children either directly or through passive information technology such as cookies. If a parent or guardian has reason to believe that a child has provided us with Personal Information (as defined below), the parent or guardian should contact us at 800-798-7802.
We do not collect any personal information unless it is provided to us voluntarily through forms or data fields. You can visit many areas of our Web sites without telling us who you are or giving us Personal Information. Certain areas of our Web sites allow you to contact us to ask questions or provide comments or other information. Please be aware that when you ask questions or provide comments or other information, you may be disclosing Personal Information.
Personal Information is information that can identify you, such as your name, street address, telephone number, e-mail address and other similar information ("Personal Information"). Please do not submit any Personal Information if you do not want it to be collected. You should be aware, however, that without providing requested information, even Personal Information, you may not be able to participate in particular features or activities that require such information.
Non-Personal Information is information that is not personal, such as questions, comments, ideas and suggestions that you provide, or information that we may collect that is not linked to any Personal Information. Non-Personal Information will be treated as non-confidential, and we may disclose and/or use that information without any obligation whatsoever to you, for any purpose and through any means.
The Partnership Web sites may use a tracking technology called a "cookie." A "cookie" is a small text file that a Web site can place on your computer's hard drive in order, for example, to collect information about your activities on the site or to track your preferences and selections. When you return to the Web site, information stored in cookies associated with that site will be transmitted back to us. With most Internet browsers, you can erase cookies from your computer's hard drive, block all cookies or even receive a warning before a cookie is placed on your system. Refer to your browser instructions or Help button to learn more about cookies. You should be aware, however, that cookies might be necessary to provide you with certain features (e.g., customized delivery of information) available on the Partnership Web sites. This information is considered Non-Personal Information.
The Partnership Web sites may also automatically collect and store Web log information relating to your computer and your visit, such as the name of the domain and host from which you access the Internet; the Internet address of the Web site from which you linked to the Partnership Web site; the date and time you accessed the Partnership Web site, how long you spent and which pages you visited; your Internet protocol (IP) address; and your computer's operating system and browser software. This information is considered Non-Personal Information.
The Partnership Web sites may also track your usage of the site through the use of pixel tags (also called clear gifs). The information collected through use of pixel tags is not personally identifiable and is considered Non-Personal Information.
If you do provide us with Personal Information we may use the information to contact you, via e-mail, regular mail, telephone or other means, to provide you with information you requested about specific products or services, provide additional future information about products or services that may be of interest to you, and to learn about and develop products and services concerning a particular disease or condition (e.g., market research). Other or additional information about use of your Personal Information may appear at the point where you are asked to provide Personal Information in a form or data field.
The Partnership will not transfer or allow access to your Personal Information to third parties, except (i) to affiliated entities within the Partnership or its individual partners, whether inside the U.S. or in other countries; (ii) to vendors and service providers who assist us in providing service to you (e.g., a fulfillment company for processing and mailing purposes); (iii) in connection with security-related or law enforcement investigations or in the course of cooperating with authorities; (iv) to comply with legal requirements or to establish or exercise our legal rights or defend against legal claims; (v) when we believe it is necessary to share information in order to assist in an investigation regarding, or to prevent, illegal activities, suspected fraud, or situations involving potential threats to the safety of any person; and (vi) upon a sale, merger, assignment or transfer of the business of the Web site to which the information relates. Any affiliated entity, vendor or service provider who is permitted access to, or to whom we transfer, Personal Information is required to keep your Personal Information confidential.
The Partnership takes reasonable precautions to keep Personal Information secure against unauthorized access and use.
If you decide you no longer wish to receive information or communications about particular products and services, or from the Partnership (for example, postal mailings, e-mails and telephone calls), you may opt out of any particular product or service or from all mailings by contacting us at: 888-786-8637.
Please note that you may continue to receive materials for a period of time while our lists are being updated.
This policy may be updated or revised from time to time, so you may want to check for updates if you access the Partnership Web sites in the future.
Thank you for your interest in the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.
IMPORTANT SAFETY INFORMATION
The effectiveness of PLAVIX is dependent on its activation to an active metabolite by the cytochrome P450
(CYP) system, principally CYP2C19 [See Warnings and Precautions (5.1)]. PLAVIX at recommended doses forms
less of
that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor
metabolizers. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary
intervention treated with PLAVIX
at recommended doses exhibit higher cardiovascular event rates than do
patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these
tests can be used as an aid in determining therapeutic strategy [See Clinical Pharmacology (12.5)]. Consider
alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers
[See Dosage and Administration (2.3)].
- PLAVIX is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
- PLAVIX is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the
product.
- The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 and by concomitant medications that interfere with CYP2C19. Avoid concomitant use of PLAVIX with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of PLAVIX.
- Thienopyridines, including PLAVIX, increase the risk of bleeding. If a patient is to undergo surgery and an antiplatelet
effect is not desired, discontinue PLAVIX 5 days prior to surgery.
- Avoid lapses in therapy, and if PLAVIX must be temporarily discontinued, restart as soon as possible. Premature
discontinuation of PLAVIX may increase the risk of cardiovascular events.
- In patients with recent TIA or stroke who are at high risk for recurrent ischemic events, the combination of aspirin and
PLAVIX has not been shown to be more effective than PLAVIX alone, but the combination has been shown to increase
major bleeding.
- TTP, sometimes fatal, has been reported following use of PLAVIX, sometimes after a short exposure (<2 weeks). TTP is
a serious condition that requires urgent treatment including plasmapheresis (plasma exchange).
- Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction.
- Avoid concomitant use of PLAVIX with omeprazole or esomeprazole, which has been shown to reduce anti-platelet activity in impaired CYP2C19 function. Consider using another acid-reducing agent with minimal or no CYP2C19 inhibitory effect on the formation of the clopidogrel active metabolite. Dexlansoprazole, lansoprazole and pantoprazole had less effect on the pharmacological activity of PLAVIX than omeprazole or esomeprazole.
- Coadministering warfarin with PLAVIX increases the risk of bleeding.
- Coadministration of PLAVIX and NSAIDs increases the risk of gastrointestinal bleeding.
- Nursing mothers: Discontinue drug or nursing, taking into consideration importance of drug to mother.
INDICATIONS
For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction
(NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary
revascularization, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death,
myocardial infarction (MI), or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia.
For patients with ST-elevation myocardial infarction (STEMI), PLAVIX has been shown to reduce the rate of death from
any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo
primary percutaneous coronary intervention is unknown.
The optimal duration of PLAVIX therapy in ACS is unknown.
For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease,
PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or
not), and other vascular death.
Please click here for Important Safety Information and U.S. Full Prescribing Information, including BOXED WARNING.